Chronic Hepatitis News

TARGET PharmaSolutions has partnered with Gilead Sciences for the TARGET-NASH observational study of nonalcoholic fatty liver disease and the TARGET-HBV observational study of hepatitis B, according to a press release.

SAN FRANCISCO — Preemptive administration of pangenotypic direct-acting antiviral therapy resulted in rapid viral suppression of hepatitis C in patients without HCV who received a heart transplantation with an HCV-positive organ, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Results from a phase 2b trial showed that Aramchol— a stearoyl coenzyme desaturase A inhibitor — significantly reduced liver fat and improved histology with excellent safety and tolerability in patients with nonalcoholic fatty liver disease, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Mavyret yielded nearly perfect SVR rates after 8 weeks of therapy in compensated cirrhosis with HCV, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Combination therapy with Kineret, Trental and zinc sulfate showed only a slight trend toward 90-day improved survival in patients with alcoholic hepatitis but otherwise showed little benefit, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — NS5A resistance-associated substitutions at several positions, including Y93, may hold information about DAA treatment response, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — U.S. states in the Appalachian region demonstrated increased rates of hepatitis B among women despite overall national rates of acute and chronic HBV remaining stable or declining among women and children, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Individuals with hepatitis C who underwent DAA therapy experienced significant reductions in both hepatocellular carcinoma and decompensation risk compared with untreated patients, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — A novel prognostic score using four objective pretransplant variables identified patients with alcoholic hepatitis who were candidates for early liver transplantation with a low risk for sustained alcohol use posttransplant, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018.